{
  "paper": {
    "doi": null,
    "pmcid": "PMC12780394",
    "title": "Global bibliometric analysis of pleural mesothelioma biomarkers (2002\u20132024): trends and emerging frontiers",
    "authors": [
      "Not specified"
    ],
    "journal": "Not specified",
    "year": 2024,
    "study_type": "bibliometric analysis",
    "eco_type": null
  },
  "extraction_provenance": {
    "extraction_pipeline": {
      "name": "medlit_pass1_extract",
      "version": "0.1.0",
      "git_commit": "39f1b7e43865f4ea820908097aed6859daeae7cf",
      "git_commit_short": "39f1b7e",
      "git_branch": "ingest-refactor",
      "git_dirty": true,
      "repo_url": "https://github.com/org/medlit"
    },
    "models": {
      "llm": {
        "name": "claude-sonnet-4-20250514",
        "version": ""
      }
    },
    "prompt": {
      "version": "v1",
      "template": "medlit_extraction_v1",
      "checksum": "sha256:f94cc0ab23940d18"
    },
    "execution": {
      "timestamp": "2026-02-23T18:23:09.176960Z",
      "hostname": "unknown",
      "python_version": "3.13.3",
      "duration_seconds": 46.98
    },
    "entity_resolution": null,
    "model_info": null
  },
  "entities": [
    {
      "id": "disease_1",
      "class": "Disease",
      "name": "pleural mesothelioma",
      "synonyms": [
        "PM",
        "malignant pleural mesothelioma",
        "malignant mesothelioma"
      ],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": "C0812413",
      "hgnc_id": null,
      "rxnorm_id": null,
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "disease_2",
      "class": "Disease",
      "name": "mesothelioma",
      "synonyms": [
        "mesothelial tumor",
        "mesothelial neoplasm"
      ],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": "C0025500",
      "hgnc_id": null,
      "rxnorm_id": null,
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "gene_1",
      "class": "Gene",
      "name": "mesothelin",
      "synonyms": [
        "MSLN"
      ],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": null,
      "hgnc_id": "HGNC:7371",
      "rxnorm_id": null,
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "gene_2",
      "class": "Gene",
      "name": "PD-L1",
      "synonyms": [
        "programmed cell death ligand-1",
        "CD274"
      ],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": null,
      "hgnc_id": "HGNC:17635",
      "rxnorm_id": null,
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "gene_3",
      "class": "Gene",
      "name": "osteopontin",
      "synonyms": [
        "OPN",
        "SPP1",
        "secreted phosphoprotein 1"
      ],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": null,
      "hgnc_id": "HGNC:11255",
      "rxnorm_id": null,
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "gene_4",
      "class": "Gene",
      "name": "BAP1",
      "synonyms": [
        "BRCA1-associated protein 1"
      ],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": null,
      "hgnc_id": "HGNC:950",
      "rxnorm_id": null,
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "gene_5",
      "class": "Gene",
      "name": "miR-182-5p",
      "synonyms": [
        "microRNA-182-5p"
      ],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": null,
      "hgnc_id": "HGNC:31586",
      "rxnorm_id": null,
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "gene_6",
      "class": "Gene",
      "name": "let-7b",
      "synonyms": [
        "microRNA let-7b"
      ],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": null,
      "hgnc_id": "HGNC:31482",
      "rxnorm_id": null,
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "gene_7",
      "class": "Gene",
      "name": "FOXO1",
      "synonyms": [
        "forkhead box O1"
      ],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": null,
      "hgnc_id": "HGNC:3819",
      "rxnorm_id": null,
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "gene_8",
      "class": "Gene",
      "name": "FOXO3",
      "synonyms": [
        "forkhead box O3"
      ],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": null,
      "hgnc_id": "HGNC:3821",
      "rxnorm_id": null,
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "drug_1",
      "class": "Drug",
      "name": "nivolumab",
      "synonyms": [
        "Opdivo"
      ],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": null,
      "hgnc_id": null,
      "rxnorm_id": "1312830",
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "drug_2",
      "class": "Drug",
      "name": "ipilimumab",
      "synonyms": [
        "Yervoy"
      ],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": null,
      "hgnc_id": null,
      "rxnorm_id": "1094833",
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "drug_3",
      "class": "Drug",
      "name": "pembrolizumab",
      "synonyms": [
        "Keytruda"
      ],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": null,
      "hgnc_id": null,
      "rxnorm_id": "1547545",
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "drug_4",
      "class": "Drug",
      "name": "pemetrexed",
      "synonyms": [
        "Alimta"
      ],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": null,
      "hgnc_id": null,
      "rxnorm_id": "282464",
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "biomarker_1",
      "class": "Biomarker",
      "name": "SMRP",
      "synonyms": [
        "soluble mesothelin-related peptide"
      ],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": null,
      "hgnc_id": null,
      "rxnorm_id": null,
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "biomarker_2",
      "class": "Biomarker",
      "name": "sPD-L1",
      "synonyms": [
        "soluble PD-L1"
      ],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": null,
      "hgnc_id": null,
      "rxnorm_id": null,
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "biomarker_3",
      "class": "Biomarker",
      "name": "microRNA",
      "synonyms": [
        "miRNA",
        "miR"
      ],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": null,
      "hgnc_id": null,
      "rxnorm_id": null,
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "exposure_1",
      "class": "Environmental_Factor",
      "name": "asbestos",
      "synonyms": [
        "asbestos exposure"
      ],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": null,
      "hgnc_id": null,
      "rxnorm_id": null,
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "therapy_1",
      "class": "Therapy",
      "name": "immunotherapy",
      "synonyms": [
        "immune checkpoint inhibitor therapy",
        "ICT"
      ],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": null,
      "hgnc_id": null,
      "rxnorm_id": null,
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "therapy_2",
      "class": "Therapy",
      "name": "CAR-T therapy",
      "synonyms": [
        "chimeric antigen receptor T-cell therapy"
      ],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": null,
      "hgnc_id": null,
      "rxnorm_id": null,
      "loinc_code": null,
      "uniprot_id": null
    }
  ],
  "evidence_entities": [
    {
      "id": "paper_1:background:1:llm",
      "class": "Evidence",
      "entity_id": null,
      "paper_id": "paper_1",
      "text_span_id": "background_1",
      "text": "Pleural mesothelioma (PM) is an aggressive malignancy that originates on the mesothelial surface of the pleura, peritoneum, pericardium, and tunica vaginalis. Due to the absence of specific clinical symptoms, early-stage diagnosis occurs in fewer than 5% of cases.",
      "confidence": 0.95,
      "extraction_method": "llm",
      "study_type": "bibliometric analysis",
      "eco_type": null,
      "source": "extracted"
    },
    {
      "id": "paper_1:introduction:2:llm",
      "class": "Evidence",
      "entity_id": null,
      "paper_id": "paper_1",
      "text_span_id": "introduction_2",
      "text": "The predominant risk factor for PM is asbestos exposure, with approximately 80% of cases linked to prior asbestos contact.",
      "confidence": 0.95,
      "extraction_method": "llm",
      "study_type": "bibliometric analysis",
      "eco_type": null,
      "source": "extracted"
    },
    {
      "id": "paper_1:discussion:3:llm",
      "class": "Evidence",
      "entity_id": null,
      "paper_id": "paper_1",
      "text_span_id": "discussion_3",
      "text": "Mesothelin is one of the widely studied biomarkers of PM, which is expressed at low levels in normal cells and undetectable in normal tissues, but is abundantly expressed in malignant mesothelioma, pancreatic cancer, ovarian cancer, lung cancer, and other cancers.",
      "confidence": 0.9,
      "extraction_method": "llm",
      "study_type": "bibliometric analysis",
      "eco_type": null,
      "source": "extracted"
    },
    {
      "id": "paper_1:discussion:4:llm",
      "class": "Evidence",
      "entity_id": null,
      "paper_id": "paper_1",
      "text_span_id": "discussion_4",
      "text": "SMRP are the only biomarkers for PM approved by the U.S. Food and Drug Administration (FDA).",
      "confidence": 0.95,
      "extraction_method": "llm",
      "study_type": "bibliometric analysis",
      "eco_type": null,
      "source": "extracted"
    },
    {
      "id": "paper_1:discussion:5:llm",
      "class": "Evidence",
      "entity_id": null,
      "paper_id": "paper_1",
      "text_span_id": "discussion_5",
      "text": "The PD-L1 protein plays a central role in the antitumor immune response. sPD-L1 concentrations were positively correlated with OS.",
      "confidence": 0.9,
      "extraction_method": "llm",
      "study_type": "bibliometric analysis",
      "eco_type": null,
      "source": "extracted"
    },
    {
      "id": "paper_1:discussion:6:llm",
      "class": "Evidence",
      "entity_id": null,
      "paper_id": "paper_1",
      "text_span_id": "discussion_6",
      "text": "miRNAs affect tumor growth, invasion and angiogenesis by binding to mRNAs, thereby influencing the expression of oncogenes and oncogenes and the activity of signaling pathways.",
      "confidence": 0.85,
      "extraction_method": "llm",
      "study_type": "bibliometric analysis",
      "eco_type": null,
      "source": "extracted"
    },
    {
      "id": "paper_1:discussion:7:llm",
      "class": "Evidence",
      "entity_id": null,
      "paper_id": "paper_1",
      "text_span_id": "discussion_7",
      "text": "One of the tumorigenic miRNAs associated with PM development is miR-182-5p. miR-182-5p's oncogenic function was first identified in melanoma, where the miRNA promotes tumor migration and invasion by inhibiting the activity of the forkhead box O3 (FOXO3) transcription factor.",
      "confidence": 0.9,
      "extraction_method": "llm",
      "study_type": "bibliometric analysis",
      "eco_type": null,
      "source": "extracted"
    }
  ],
  "relationships": [
    {
      "subject": "exposure_1",
      "predicate": "INCREASES_RISK",
      "object": "disease_1",
      "evidence_ids": [
        "paper_1:introduction:2:llm"
      ],
      "source_papers": [
        "paper_1"
      ],
      "confidence": 0.95,
      "properties": {
        "percentage": "80%"
      },
      "section": "introduction",
      "asserted_by": "llm",
      "resolution": null,
      "note": null
    },
    {
      "subject": "gene_1",
      "predicate": "INDICATES",
      "object": "disease_1",
      "evidence_ids": [
        "paper_1:discussion:3:llm"
      ],
      "source_papers": [
        "paper_1"
      ],
      "confidence": 0.9,
      "properties": {
        "expression_level": "abundantly expressed"
      },
      "section": "discussion",
      "asserted_by": "llm",
      "resolution": null,
      "note": null
    },
    {
      "subject": "biomarker_1",
      "predicate": "INDICATES",
      "object": "disease_1",
      "evidence_ids": [
        "paper_1:discussion:4:llm"
      ],
      "source_papers": [
        "paper_1"
      ],
      "confidence": 0.95,
      "properties": {
        "regulatory_status": "FDA approved"
      },
      "section": "discussion",
      "asserted_by": "llm",
      "resolution": null,
      "note": null
    },
    {
      "subject": "biomarker_1",
      "predicate": "SAME_AS",
      "object": "gene_1",
      "evidence_ids": [
        "paper_1:discussion:3:llm",
        "paper_1:discussion:4:llm"
      ],
      "source_papers": [
        "paper_1"
      ],
      "confidence": 0.9,
      "properties": {},
      "section": "discussion",
      "asserted_by": "llm",
      "resolution": null,
      "note": "SMRP is derived from mesothelin expression"
    },
    {
      "subject": "gene_2",
      "predicate": "ASSOCIATED_WITH",
      "object": "disease_1",
      "evidence_ids": [
        "paper_1:discussion:5:llm"
      ],
      "source_papers": [
        "paper_1"
      ],
      "confidence": 0.9,
      "properties": {
        "correlation": "positive correlation with overall survival"
      },
      "section": "discussion",
      "asserted_by": "llm",
      "resolution": null,
      "note": null
    },
    {
      "subject": "biomarker_3",
      "predicate": "INDICATES",
      "object": "disease_1",
      "evidence_ids": [
        "paper_1:discussion:6:llm"
      ],
      "source_papers": [
        "paper_1"
      ],
      "confidence": 0.85,
      "properties": {
        "mechanism": "affects tumor growth, invasion and angiogenesis"
      },
      "section": "discussion",
      "asserted_by": "llm",
      "resolution": null,
      "note": null
    },
    {
      "subject": "gene_5",
      "predicate": "ASSOCIATED_WITH",
      "object": "disease_1",
      "evidence_ids": [
        "paper_1:discussion:7:llm"
      ],
      "source_papers": [
        "paper_1"
      ],
      "confidence": 0.9,
      "properties": {
        "role": "tumorigenic",
        "mechanism": "promotes tumor migration and invasion"
      },
      "section": "discussion",
      "asserted_by": "llm",
      "resolution": null,
      "note": null
    },
    {
      "subject": "gene_5",
      "predicate": "ASSOCIATED_WITH",
      "object": "gene_8",
      "evidence_ids": [
        "paper_1:discussion:7:llm"
      ],
      "source_papers": [
        "paper_1"
      ],
      "confidence": 0.9,
      "properties": {
        "interaction": "inhibits FOXO3 transcription factor activity"
      },
      "section": "discussion",
      "asserted_by": "llm",
      "resolution": null,
      "note": null
    },
    {
      "subject": "drug_1",
      "predicate": "TREATS",
      "object": "disease_1",
      "evidence_ids": [],
      "source_papers": [
        "paper_1"
      ],
      "confidence": 0.8,
      "properties": {
        "combination": "with ipilimumab"
      },
      "section": "results",
      "asserted_by": "llm",
      "resolution": null,
      "note": null
    },
    {
      "subject": "drug_2",
      "predicate": "TREATS",
      "object": "disease_1",
      "evidence_ids": [],
      "source_papers": [
        "paper_1"
      ],
      "confidence": 0.8,
      "properties": {
        "combination": "with nivolumab"
      },
      "section": "results",
      "asserted_by": "llm",
      "resolution": null,
      "note": null
    },
    {
      "subject": "drug_3",
      "predicate": "TREATS",
      "object": "disease_1",
      "evidence_ids": [],
      "source_papers": [
        "paper_1"
      ],
      "confidence": 0.8,
      "properties": {
        "trial": "KEYNOTE-028"
      },
      "section": "results",
      "asserted_by": "llm",
      "resolution": null,
      "note": null
    },
    {
      "subject": "therapy_1",
      "predicate": "TREATS",
      "object": "disease_1",
      "evidence_ids": [],
      "source_papers": [
        "paper_1"
      ],
      "confidence": 0.85,
      "properties": {
        "emerging_hotspot": "true"
      },
      "section": "results",
      "asserted_by": "llm",
      "resolution": null,
      "note": null
    }
  ],
  "notes": [
    "This bibliometric analysis covers 662 publications on pleural mesothelioma biomarkers from 2002-2024",
    "The study identifies immunotherapy and epigenetics as emerging research hotspots",
    "SMRP is currently the only FDA-approved biomarker for pleural mesothelioma",
    "Clinical translation of biomarkers remains limited despite growing research interest"
  ]
}